POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT)
Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 226-227
10.1002/hon.41_2630